Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FHDA0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,532
Award facts
- Contract value 100% obligated
- $25,532.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $25.5K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 capsules of Xtandi 40 mg. The award, issued on January 12, 2026, with an ultimate completion date of January 13, 2026, utilizes firm fixed-price contracting with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded in November 2025 with a $499.9 billion ceiling value and extends through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for Department of Defense healthcare operations, leveraging its established performance on numerous prior delivery orders to fulfill specialized medical supply requirements across military healthcare facilities. The company maintains an extensive product portfolio encompassing branded and generic prescription medications, oncology treatments, biologics, vaccines, and medical consumables. The PPV-G GEN V program, structured as a multi-award contract vehicle with a $30.3 billion total acquisition strategy, enables the Defense Logistics Agency to issue firm fixed-price delivery orders for recurring pharmaceutical needs, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting global military medical operations.
Quick answers
Who was awarded contract SPE2DR26FHDA0?
SPE2DR26FHDA0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FHDA0 worth?
The government has obligated $25,532 on SPE2DR26FHDA0.
Is contract SPE2DR26FHDA0 an order under another contract?
Yes. SPE2DR26FHDA0 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHDA0 competed?
The extent of competition for SPE2DR26FHDA0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award